ES2151927T3 - Interleuquina-15. - Google Patents

Interleuquina-15.

Info

Publication number
ES2151927T3
ES2151927T3 ES94915781T ES94915781T ES2151927T3 ES 2151927 T3 ES2151927 T3 ES 2151927T3 ES 94915781 T ES94915781 T ES 94915781T ES 94915781 T ES94915781 T ES 94915781T ES 2151927 T3 ES2151927 T3 ES 2151927T3
Authority
ES
Spain
Prior art keywords
polypeptides
derivatives
mammalian
interleuquina
etf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94915781T
Other languages
English (en)
Inventor
Kenneth H Grabstein
Dirk M Anderson
June R Eisenman
Charles Rauch
Victor Fung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Priority claimed from ZA942636A external-priority patent/ZA942636B/xx
Application granted granted Critical
Publication of ES2151927T3 publication Critical patent/ES2151927T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE DISPONE UN POLIPEPTIDO DE FACTOR DE CELULAS T DERIVADAS DE EPITELIO DE MAMIFERO ("ETF") A LA QUE AQUI SE LLAMA INTERLEUCINA15 ("IL-15"), DERIVADOS DEL MISMO, SECUENCIAS DE ADN, MOLECULAS DE ADN RECOMBINANTE Y CELULAS HUESPED TRANSFORMADAS QUE PRODUCEN POLIPEPTIDOS DE IL-15. EN CONCRETO, ESTA INVENCION PROPORCIONA POLIPEPTIDOS AISLADOS DE IL-15 DE MAMIFERO Y DERIVADOS DE LOS MISMOS QUE REGULAN SUCESOS EN LA PROLIFERACION DE LINFOCITOS T.
ES94915781T 1994-04-06 1994-04-06 Interleuquina-15. Expired - Lifetime ES2151927T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/US1994/003793 WO1995027722A1 (en) 1994-04-06 1994-04-06 Interleukin-15
NZ266264A NZ266264A (en) 1994-04-06 1994-04-06 Mammalian epithelium-derived t-cell factor called interleukin-15
ZA942636A ZA942636B (en) 1994-04-06 1994-04-18 Interleukin-15
OA60897A OA10375A (en) 1994-04-06 1996-09-27 Interleukin-15

Publications (1)

Publication Number Publication Date
ES2151927T3 true ES2151927T3 (es) 2001-01-16

Family

ID=33314371

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94915781T Expired - Lifetime ES2151927T3 (es) 1994-04-06 1994-04-06 Interleuquina-15.

Country Status (11)

Country Link
EP (1) EP0772624B1 (es)
AT (1) ATE196315T1 (es)
CA (1) CA2186747C (es)
DE (1) DE69425906T2 (es)
DK (1) DK0772624T3 (es)
ES (1) ES2151927T3 (es)
GR (1) GR3035019T3 (es)
NZ (1) NZ266264A (es)
OA (1) OA10375A (es)
PT (1) PT772624E (es)
WO (1) WO1995027722A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69622854T2 (de) * 1995-04-02 2003-04-10 Chugai Seiyaku K.K., Tokio/Tokyo Arzneimittel zur Heilung von Thrombozytopenie
CN1200037A (zh) 1995-10-17 1998-11-25 韦恩州立大学 鸡白细胞介素－15及其用途
US6509313B1 (en) 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
US6451308B1 (en) 1996-04-26 2002-09-17 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
EP1627918A1 (en) * 1996-04-26 2006-02-22 Beth Israel Deaconess Medical Center, Inc. Antagonists of interleukin-15
US6001973A (en) * 1996-04-26 1999-12-14 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
US6087172A (en) * 1997-10-31 2000-07-11 Hisamitsu Pharmaceutical Co., Inc. Ribozymes targeted to human IL-15 mRNA
US5985663A (en) * 1998-11-25 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of interleukin-15 expression
AU3373300A (en) * 1999-02-24 2000-09-14 Wistar Institute Of Anatomy And Biology, The Method of modifying cytotoxic cells and uses thereof
US6828147B1 (en) 1999-02-24 2004-12-07 The Wistar Institute Of Anatomy And Biology Method of modifying cytotoxic cells and uses thereof
AU6158501A (en) 2000-05-12 2001-11-26 Beth Israel Hospital Compositions and methods for achieving immune suppression
CU23093A1 (es) * 2002-10-09 2005-10-19 Ct Ingenieria Genetica Biotech Composición vacunal que comprende interleucina-15 (il-15)
CN100427597C (zh) * 2003-11-26 2008-10-22 中国医学科学院基础医学研究所 可用于生产人重组白细胞介素-15的原核表达工程菌及纯化方法
CU23472A1 (es) 2004-09-17 2009-12-17 Ct Ingenieria Genetica Biotech Péptido antagonista de la interleucina-15
ES2382775T3 (es) * 2004-10-08 2012-06-13 Government Of The United States Of America,As Represented By The Secretary, Department Of Health And Human Services Inmunoterapia adoptiva con supervivencia de linfocitos T potenciada.
NZ581779A (en) 2005-05-17 2011-09-30 Univ Connecticut Composition and methods for immunomodulation in an organism comprising interleukin-15 polypeptide and interleukin-15 receptor subunit A polypeptide complex
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
US9303080B2 (en) 2006-01-13 2016-04-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells
ES2470772T3 (es) 2007-05-11 2014-06-24 Altor Bioscience Corporation Moléculas de fusión y variantes de IL-15
AU2008269032B2 (en) 2007-06-27 2013-12-05 Novartis Ag Complexes of IL-15 and IL-15Ralpha and uses thereof
WO2009135031A1 (en) 2008-04-30 2009-11-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Substituted il-15
EP2464377B1 (en) 2009-08-14 2016-07-27 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Use of il-15 to increase thymic output and to treat lymphopenia
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
CN107880136B (zh) 2010-09-21 2021-11-12 阿尔托生物科学有限公司 多聚体il-15可溶性融合分子与其制造与使用方法
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
WO2013088114A1 (en) 2011-12-12 2013-06-20 Cell Medica Limited Process of expanding t cells
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
PL2812431T3 (pl) 2012-02-09 2020-02-28 Baylor College Of Medicine Mieszanki peptydowe do wytwarzania wielowirusowych CTL o szerokiej swoistości
EP2986312B1 (en) 2013-04-19 2021-12-15 Cytune Pharma Cytokine derived treatment with reduced vascular leak syndrome
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
MA39711A (fr) 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
AU2015284248B2 (en) 2014-06-30 2020-04-16 Altor Bioscience Corporation IL-15-based molecules and methods of use thereof
CN113791213A (zh) 2015-09-18 2021-12-14 贝勒医学院 来自病原体的免疫原性抗原鉴定以及与临床效力的相关性
JP7185530B2 (ja) 2016-06-13 2022-12-07 トルク セラピューティクス， インコーポレイテッド 免疫細胞機能を促進するための方法および組成物
CN118562016A (zh) 2016-10-21 2024-08-30 艾尔特生物科技公司 基于多聚体il-15的分子
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
SG10202111394XA (en) 2017-04-13 2021-12-30 Senti Biosciences Inc Combinatorial cancer immunotherapy
CN111093688A (zh) 2017-05-15 2020-05-01 尼克塔治疗公司 长效白细胞介素-15受体激动剂以及相关免疫治疗组合物和方法
KR102008429B1 (ko) * 2017-06-30 2019-08-07 아주대학교산학협력단 인터루킨-15/인터루킨-15 수용체 알파-Fc 복합체를 포함하는 염증질환 치료 또는 예방용 조성물
EP3678701A4 (en) 2017-09-05 2021-12-01 Torque Therapeutics, Inc. THERAPEUTIC PROTEIN COMPOSITIONS AND METHOD FOR MANUFACTURING AND USING THEREOF
JP2022512766A (ja) 2018-10-17 2022-02-07 センティ バイオサイエンシズ インコーポレイテッド 組み合わせがん免疫療法
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US20220195396A1 (en) * 2020-12-03 2022-06-23 Century Therapeutics, Inc. Genetically Engineered Cells and Uses Thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
WO2023086772A1 (en) 2021-11-12 2023-05-19 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
WO2024102636A1 (en) 2022-11-07 2024-05-16 Xencor, Inc. Bispecific antibodies that bind to b7h3 and mica/b

Also Published As

Publication number Publication date
PT772624E (pt) 2001-03-30
OA10375A (en) 2001-11-16
DK0772624T3 (da) 2000-11-13
NZ266264A (en) 1997-01-29
WO1995027722A1 (en) 1995-10-19
ATE196315T1 (de) 2000-09-15
GR3035019T3 (en) 2001-03-30
EP0772624B1 (en) 2000-09-13
EP0772624A1 (en) 1997-05-14
DE69425906D1 (en) 2000-10-19
EP0772624A4 (en) 1997-07-02
CA2186747C (en) 2009-01-27
CA2186747A1 (en) 1995-10-19
DE69425906T2 (de) 2001-03-29

Similar Documents

Publication Publication Date Title
ATE196315T1 (de) Interleukin-15
NO975437D0 (no) Nytt CD40L-mutein
ATE353906T1 (de) Cd27 ligand
DK0669929T3 (da) Elk-ligand, et cytokin
DE69725587D1 (de) Verwendung von wnt polypeptiden
DE69535147D1 (de) Überexpression von säugetier- und virusproteinen
ATE389666T1 (de) Hohe expressionsrate von proteinen
MX9503362A (es) Nuevos anticuerpos br96 mutantes y equivalentes funcionales que reaccionan con carcinomas humanos.
NO854460L (no) Syntetisk hepatitis-b-vaksine inbefattende baade t-celle og b-celledeterminanter.
MX9708426A (es) Polipeptido hk2 de variante estable.
DE59410132D1 (de) Humanes zirkulierendes cytokin cc-1
MX9702341A (es) Citoquina designada lerk-6.
AU656353B2 (en) New variants derived from interferons of type I, production process thereof and their applications
SE9401380D0 (sv) Ny celltillväxt-relaterad peptid och användning därav
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune
NO974713D0 (no) Gener som koder for lymfocyttinterferon-regulatorisk faktor (LSIRF) polypeptider
AU7378087A (en) Interleukin-2 induced antineoplastic peptide
AU1305097A (en) Protein induced by deprenyl$m(3)
ITMI931034A1 (it) Processo per la preparazione di proteine inibenti i ribosomi

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 772624

Country of ref document: ES